Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients
Authors:
- 1 December 2002
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 8 (6) , 492-494
Abstract
As response to interferon beta (IFNB) treatment, a 50% reduction of the mean relapse rate compared to pretreatment values has been reported. However, individual responses vary considerably, ranging from no reduction in exacerbation frequency to complete suppression of relapses for at least two years. At the moment, valid predictors for IFNB response are lacking. Here we present a prospective evaluation of 33 patients with primary relapsing multiple sclerosis, who were followed for two years of IFNB treatment. A low interferon gamma (IFG) production before treatment predicted a two-year term without exacerbations in 68.8% of cases correctly, whereas a high pretreatment IFG production implied the risk of at least one relapse in the first two years in 70.6%. These preliminary results encourage further evaluation of IFG as predictor of an IFNB treatment response.Keywords
This publication has 19 references indexed in Scilit:
- Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patientsMultiple Sclerosis Journal, 2000
- Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patientsJournal of Neuroimmunology, 1999
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- In vitro TNF-α, IL-2 and IFN-γ production as markers of relapses in multiple sclerosisClinical Neurology and Neurosurgery, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERONThe Lancet, 1987
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983